Doxorubicin in combination with cisplatin, 5‐flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study - Katzenstein, Howard M.; Malogolowkin, Marcio H.; Krailo, Mark D.; Piao, Jin; Towbin, Alexander J.; McCarville, M. Beth; Tiao, Gregory M.; Dunn, Stephen P.; Langham, Max R.; McGahren, Eugene D.; Finegold, Milton J.; Ranganathan, Sarangarajan; et al. (Cancer, 2022)
Keywords: 5-Fluorouracil; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Aspartate aminotransferase; Children; Cisplatin; Cisplatin - adverse effects; Clinical trials; Diagnosis; Doxorubicin; Doxorubicin - adverse effects; Feasibility Studies; hepatoblastoma; Hepatoblastoma - drug therapy; Hepatoblastoma - pathology; Histology; Humans; Hypokalemia; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - pathology; Mucositis; Neutropenia; Oncology; Patients; pediatric liver transplant; pediatric liver tumor; Pretreatment Extent of Disease (PRETEXT); Survival; Toxicity; Treatment Outcome; Vincristine; Vincristine - adverse effects; hepatoblastoma; toxicity; pediatric liver transplant; pediatric liver tumor; doxorubicin; cisplatin; Pretreatment Extent of Disease (PRETEXT)